Naltrexone as a treatment for repetitive self-injurious behaviour:an open-label trial.

Abstract

These preliminary observations are consistent with the hypothesis that the endogenous opioid system is involved in cases of SIB that are accompanied by analgesia and dysphoria reduction. Additional placebo-controlled studies that explore the effectiveness of naltrexone in treating patients with this syndrome are warranted.